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Background 
Considerable controversy exists regarding the role of anti- 
biotics in managing exacerbations of chronic bronchitis (1). 
In fact, a recent British survey (2) has shown that unless 
patients have a history of coexistent cardiopulmonary dis- 
ease and frequent exacerbations, they are likely to recover 
from exacerbation whatever their treatment. This concurs 
with the opinion of Murphy and Sethi (3) that most 
infections in chronic bronchitis are mucosal diseases that 
will resolve spontaneously. On the other hand, some 
exacerbations may not be infective in origin but rather 
represent a fluctuation in the severity of the patient’s 
underlying bronchospasm (4). 
In any case, supposing that the deterioration is due to 
infection, it is often difficult to identity the causative 
organism (5). Whereas the initial insult resulting in 
increased cough and expectoration is likely to be viral 
(viruses have been implicated in 44-63.3% of exacer- 
bations, particularly influenza and parainfluenza viruses, 
respiratory syncytial virus and adenovirus) (6), the fact of 
bacterial invasion in many patients is also well established 
and there is even evidence that viral exacerbations can be 
complicated by secondary bacterial infection (7). However, 
no reliable method of differentiating exacerbations caused 
by bacteria from exacerbations caused by other agents 
currently exists, since both bacterial and non-bacterial 
exacerbations have the same degree of fever, leukocytosis, 
hypoxaemia and symptoms. Nevertheless, current studies 
indicate that between 80 and 100% of domiciliary patients 
with acute exacerbations of chronic bronchitis will receive 
an antibiotic, usually a p-lactam, but between 13 and 
25% will return promptly, complaining of continuing 
symptoms (2,8). 
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A recent meta-analysis of nine randomized placebo- 
controlled trials of antibiotic therapy for exacerbation of 
COPD has suggested a small but statistically significant 
improvement due to antimicrobial treatment (9). Particu- 
larly, Anthonisen et al. (10) have published the best evi- 
dence that antibiotics are useful in the treatment of acute 
exacerbations of chronic bronchitis. These authors showed 
that benefit from antibiotic therapy during exacerbation 
could only be demonstrated in patients with moderate to 
severe exacerbations. Exacerbations were defined in terms 
of symptoms on the basis of increased dyspnea, sputum 
volume, and sputum purulence. In the same study, no 
benefit from antibiotics was demonstrated for milder 
exacerbations involving only one of these clinical par- 
ameters. However, the recent consensus statement 
of the European Respiratory Society declares that 
‘when sputum becomes purulent, patients are treated on 
empirical grounds with a 7-14 day course of antibiotics, 
regardless of severity, presumably in the conviction that 
some advantage may accrue (11). Therefore, although some 
authors (12) have cogently argued the case for the aban- 
donment of chemotherapy for acute exacerbations of 
chronic bronchitis of relatively minor severity, it is likely 
that antibiotics will continue to be prescribed, most 
commonly on an empirical basis, also because there is a 
sub-group of patients who are less likely to recover from an 
exacerbation (13). 
The choice of antibiotics must observe some basic con- 
siderations (14). In fact, microbiological activity of the 
compound and its spectrum, as well as its tolerance, its 
blood and tissue pharmacokinetics, its dosing regimen, and 
its cost, which is fundamental in this period of economic 
crisis, are relevant to the choice of treatment. 
Because antibiotic therapy is usually empirical, the phy- 
sician must take into account the potential pathogens 
[mainly, Haemophilus injuenzae, Streptococcus pneumoniae, 
and Moraxella catarrhalis (1,3)] and their current suscepti- 
bilities to available antibiotics. 
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Pharmacodynamics of Antibiotics 
The susceptibility of bacteria to specific antibiotics must 
constantly be determined. The minimal inhibitory and 
bactericidal concentrations (MIC and MBC) have been the 
major parameters used to quantify the activity of an 
antimicrobial against the infecting pathogen. They are still 
widely used to judge the effectiveness of antibiotics. How- 
ever, the MIC and MBC reflect only the net drug effects 
over a fixed time of incubation. Moreover, it should not 
be forgotten that there is a noticeable difference between 
the bacteriological response, which depends on the anti- 
microbial activity of tested agent in artificial media in the 
absence of any host factors, and the clinical outcome, which 
is related to the interaction with the host. Therefore, 
deciding whether the results show the organism to be 
susceptible requires an understanding of the kinetics of the 
antimicrobial agent. In fact, the kinetics of antibacterial 
drugs, principally as they relate to antimicrobial activity, 
are presumably the best indicators of the optimal method of 
drug administration and thus of maximum efficacy (15). 
Several pharmacokinetic surrogate relationships have been 
examined for various classes of antibiotics (16). These 
surrogates correlate disparate pharmacokinetic parameters 
to a measure of the pharmacodynamic interaction (i.e. the 
MIC). One of these surrogate relationships examines the 
peak serum concentration (C,,,) of the antimicrobial rela- 
tive to the MIC value (i.e. the C,,.JMIC ratio). The time 
that the serum concentration of a given agent exceeds the 
MIC (DMIC), and the area under the inhibitory serum 
concentration-versus-time curve (AUIC) are other surro- 
gate relationships. Several studies have identified specific 
pharmacokinetic/pharmacodynamic parameters that are 
important in determining bacteriological efficacy. The AUC 
of drug exposure has proven to be the best predictor of 
efficacy for aminoglycosides, quinolones and azithromycin, 
the newer streptogramins and the oxazolidinones. In con- 
trast, in all cases where a-lactams, typical macrolides and 
co-trimoxazole have been studied, it is T>MIC that has 
proven to be the best predictor of in viva killing (17). 
Interrelationship between 
Pharmacokinetics and Pharmacodynamics 
One of the major problems faced when treating bronchial 
infections is the need to achieve effective antibiotic levels at 
the site of infection (4). Bacteria that cause bronchial 
infections are generally not invasive and, therefore, serum 
levels of antibiotic are less important and the old dogma 
that high serum concentrations are the basis for effective 
antibacterial treatment is no longer valid in some cases (18). 
Most infections occur in the tissue of the body rather than 
in the blood so that it is accepted today that appropriate 
antibiotic therapy requires achievement of significant con- 
centrations of antibiotics at the site of infection long 
enough to eliminate the invading pathogen. Thus, the 
development of dosing schedules for most antimicrobials 
has been based on the postulate that levels of drug need to 
be above the MIC at the site of infection for most or all of 
the dosage interval. 
Two different components are integral to this process. 
The first is pharmacokinetics, which is concerned with drug 
absorption, distribution, metabolism and excretion. This 
activity determines the concentration of a drug over time in 
serum, tissues and body fluids and, most important in 
antibiotic therapy, at the site of infection for a given dosing 
regimen. Tissue penetration regulates the clinical effective- 
ness and toxic potential of antibacterial agents. The second 
component is pharmacodynamics, which involves the rela- 
tionship between drug concentration and its pharmacology, 
toxicology and, in the case of antibacterial therapy, anti- 
microbial effects. The time course of antimicrobial therapy 
is a reflection of the interrelationship between pharmaco- 
kinetics and pharmacodynamics (19). 
Two parameters of antimicrobial activity are important 
in characterizing the time-course of antimicrobial activity. 
The first is the impact of increasing concentration on the 
bactericidal activity of the drug. The second is the presence 
or absence of persistent inhibitory effects that alter the 
regrowth of bacteria following drug exposure (20-22). 
Based on these two parameters, antimicrobial agents can 
be divided into three groups (23). The first group, which 
includes the penicillins, cephalosporins and aztreonam, 
exhibits minimal concentration-dependent killing and pro- 
duces short or no persistent effects with most bacteria. 
Higher concentrations do not significantly enhance the rate 
or extent of bactericidal activity, but they might cause the 
so called ‘Eagle effect’ that is characterized by a decreasing 
rate of killing at these concentrations (24). Furthermore, 
the regrowth begins soon after serum and tissue levels fall 
below MIC. The goal of a dosing regimen for antibiotics of 
this type is to maximize the time during which the organism 
is exposed to the drug, since the bactericidal activity corre- 
lates more to duration than to magnitude of dose. Specifi- 
cally, time above MIC is the most crucial consideration. The 
second group of drugs, which includes the carbapenems, 
vancomycin, clindamycin and macrolides, is similar, in that 
these agents are effective at MIC, but unlike the first group, 
they have prolonged persistent effects. Again, exposure time 
is an important parameter of efficacy, yet these drugs do not 
need to be above MIC throughout the dosing interval to 
have maximal bactericidal efficacy. The third group, which 
includes the aminoglycosides, fluoroquinolones and metro- 
nidazole, is characterized by increasing bactericidal potency 
at higher levels and by prolonged persistent effects. The aim 
of a dosing regimen with these drugs is to maximize 
concentration or attain high peak serum and tissue levels. 
Furthermore, long dosing intervals should be possible, 
since the prolonged persistent effects will prevent bacterial 
reg .owth when serum and tissue levels fall below MIC. 
Although the major determinant of efficacy with 
Blactams is the time that drug concentrations at the site of 
infection exceed the MIC for the pathogen, several studies 
from Craig’s laboratory have allowed the elaboration of a 
new interesting concept. One of these studies demonstrated 
that there was a very poor relationship between the number 
of colony-forming units of Klebsiella pneumoniae remaining 
in the lungs of neutropenic mice and the peak-MIC and 
TOPICAL REVIEW 897 
24 h AUC-MIC ratios at the end of 24 h of cefotaxime 
therapy (19). However, there was a highly significant cor- 
relation of bacterial numbers with the duration of time that 
serum levels exceeded the MIC. An in viva bacteriostatic 
effect was observed when levels were above the MIC for 
approximately 40”/0 of the dosing interval, whereas maxi- 
mum killing was approached when levels were above the 
MIC for 60-70% of the time. Analogous correlations 
between efficacy and time above MIC have been found 
with several broad-spectrum cephalosporins (ceftazidime 
and ceftriaxone) against both Gram-positive and Gram- 
negative bacteria (25-27) and with amoxicillin, 
co-amoxiclav and cefpodoxime against penicillin- 
intermediate and penicillin-resistant S. pneumoniae (Andres 
et al. abstract presented at the 35th ICAAC, 1995, and 
Urban et ul. abstract presented at the 19th ICC, 1995). 
Therefore, based on the pharmocodynamic characteristics 
of P-lactam antibiotics, the aim for a highly effective dosing 
regimen would be to provide levels above the MIC for 
60-70% of the dosing interval, but a bacteriostatic effect is 
likely to be sufficient for effective therapy because most 
patients with antimicrobials have neutrophils (19). Conse- 
quently, at least from animal studies, 40-50X of the dosing 
interval should suffice for good bacteriological efficacy. 
This means that there are real differences amongst the 
p-lactam antibiotics in terms of how much coverage is 
needed to achieve a static or a fully bactericidal effect (28). 
Clinical Validation of Pharmacokinetic 
and Pharmacodynamic Parameters of 
Efficacy 
Only few human studies have investigated the relationship 
between pharmacokinetic and pharmacodynamic par- 
ameters and clinical efficacy. Schentag et al. (29) have 
reported a clear correlation between the length of time per 
day above the MIC and the time to eradicate the pathogen 
from the tracheal aspirate in intubated intensive care 
patients who were given cefmenoxime for nosocomial pneu- 
monia. Craig (30) looked at bacteriological cure with repeat 
tympanic membrane punctures in patients suffering from 
otitis media caused by S. pneumoniae or W. inzuenzae and 
treated with erythromycin or clarithromycin. The duration 
of time that serum levels exceeded the MIC for S. pneumo- 
niae was high for both these agents (greater than 88% of the 
dosing interval), and they both did exceedingly well in 
eradicating the pneumococcus from the middle ear fluid 
(bacteriological cure 93-100%). On the other hand, the data 
for H. infruenzae infections give a different picture with a 
very low PMIC and an exceedingly poor bacteriological 
response rate (15-20%), because the MICs of these two 
macrolides against H. injkenzae are high. Craig and Andes 
(31) have compiled data from literature and compared the 
correlation between time above MIC and bacteriological 
cure rate for S. pneumoniae and H. injfuenzae in patients 
with acute otitis media. The data showed that for many 
p-lactam antibiotics, an 855100% bacteriological cure rate 
was obtained when the time above MIC was 40% of the 
dosing interval. 
Evidently, papers that support the importance of the 
interrelationship between pharmacokinetics and pharmaco- 
dynamics in inducing a good clinical and bacteriological 
outcome are insufficient; therefore, we need more documen- 
tation. Ideally, when we want to investigate the efficacy of a 
new antibiotic, we should always design the study so that 
microbiological (MICs and MBCs) and pharmacokinetic 
data should be obtained. In this way, we could analyse the 
relationship between pharmacokinetic and pharmaco- 
dynamic parameters and the clinical and microbiological 
outcome. This approach requires a close cooperation 
between the clinician, the clinical pharmacologist and the 
microbiologist. If a cooperation between the clinician and 
the microbiologisit is instituted, the participation of the 
clinical pharmacologist is more unreliable due to the scar- 
city of this professional figure. Moreover, the collection of 
pharmacokinetic data is always problematic and expensive. 
In any case, this approach would allow the carrying out of 
clinical studies in only few very qualified settings. This 
limitation would not reduce the number of our scientific 
notions but, on the contrary, it would render a real benefit 
to the literature cutting the number of those studies which 
are scantily useful because they do not furnish any new 
essential information. 
Role of Pharmacokinetics and 
Pharmacodynamics in Choosing 
Appropriate Antibiotic and Dosage 
Regimen for Treating Acute 
Exacerbations of Chronic Bronchitis 
Sites of pulmonary infections can be schematically divided 
into extracellular and intracellular sites and are differently 
affected by respiratory pathogens. The bronchial lumen, 
bronchial mucous layer and bronchial mucosa are sites 
of acute bacterial infection in patients with infectious 
exacerbation of chronic bronchitis (32) although 
sputum concentrations of an antibiotic may be the most 
important. 
Considering that concentrations of antibiotics in these 
different sites are considered potentially predictive of the 
outcome of therapy in acute exacerbations of chronic 
bronchitis, compounds should be preferred that are known 
to penetrate these sites, reaching concentrations that inhibit 
or kill the aetiological micro-organisms (33). Work by 
Maesen et al. (34) showed that in treating patients with 
acute exacerbation of chronic bronchitis infected with H. 
inzuenzae, a dose of 200 mg ampicillin failed to eradicate 
the organism since the sputum concentrations achieved did 
not exceed the MIC of the organism; a sputum/serum ratio 
of 13-20X expressed a dose-dependent effect with clinical 
outcome related to the length of time over which ampicillin 
sputum levels were superior to MICs for H. influenxe. 
Sputum concentrations of less than 0,5,~~g/rnl following 
dosage of cefaclor of up to 500 mg compared unfavourably 
with the MICs for H. injuenzae and A4. cwtarrhalis and 
were associated with clinical failure (35). Cefodizime 
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was compared with cefotaxime (36) and minocyline with 
doxycycline (37). Both cephalosporins gave high serum 
levels, low sputum levels and good results, whilst the 
tetracyclines produced low serum levels, high sputum levels 
but much poorer clinical results. Thus, in relation to the 
MICs for relevant pathogens involved in respiratory tract 
infections, the concentrations achieved in the airway secre- 
tions are marginal, and may to some extent contrast with 
the satisfactory clinical response the drug has demonstrated 
in controlled clinical trials. This is particularly true of the 
p-lactam antibiotics which are located extracellularly. On 
the other hand, the relatively high concentrations in sputum 
and bronchial secretions observed with the intracellularly 
located quinolones, may be of less significance as the site 
of infection is usually extracellular (38). Since there is a 
macroscopic diversity in the penetration of different antibi- 
otic classes into the tissues and secretions of the respiratory 
tract, the implications of these factors for the treatment of 
acute exacerbations of chronic bronchitis are worthy of 
consideration (39). 
In any case, dosages and dosing intervals of antibiotics 
for the exacerbations of chronic bronchitis should be 
designed not only according to their tissue penetration, but 
also with full consideration of the relationship between 
their pharmacokinetics and pharmacodynamics. 
A variety of antimicrobial drugs are available that have 
distinct pharmacokinetic and pharmacodynamic properties. 
The challenge for the clinician is to apply these properties to 
the use of antimicrobials. 
Data generated by the Alexander Project, an inter- 
national multicentre study monitoring trends in the anti- 
microbial susceptibilities of community-acquired lower 
respiratory tract pathogens, are extremely useful for appli- 
cation of the interrelationship between pharmacokinetics 
and pharmacodynamics (2840). For S. pneumoniue, 
co-amoxiclav is effective with varying dosage regimens 
providing around 40% time above the MIC,, in contrast to 
the oral cephalosporins (cefaclor, cefuroxime and cefixime) 
and the macrolides (erythromycin, clarithromycin and 
azithromycin) for which serum concentrations do not 
exceed the MIC,,. For H. inJuenzae, co-amoxiclav and 
cefixime are suitable antibiotics whereas macrolides have 
limited activity. With the exception of amoxycillin, all the 
p-lactam and macrolide antibiotics reviewed performed 
better against M catarrhalis than against the other two 
pathogens. Quinolones (ciprofloxacin and ofloxacin), for 
which AUC is the relevant pharmacodynamic param- 
eter, had the greatest activity against H. in@enzae and 
M catarrhalis at MIC,,, but were less effective against 
S. pneumoniae. 
Obviously, these data, although useful, are partial; in 
fact, there are many other interesting drugs that have not 
been evaluated. Moreover, they apply only to bacteria 
isolated in specific centres, and do not report the real 
pathogen distribution and antimicrobial resistance patterns 
for each country. Therefore, we think that the best way to 
treat patients is to consider the local MICs against the 
common respiratory pathogens and also the peculiar phar- 
macokinetic characteristics of each antibiotic and how they 
fit with each patient. 
Since the kinetics of antimicrobial drugs as they relate to 
antimicrobial activity are the best indicators of the optimal 
method of drug administration and thus of maximum 
efficacy, it is fundamental to optimize the dosage regimen 
by considering the pharmacokinetic behaviour of each 
antimicrobial drug. We will illustrate two examples of this 
concept. 
Dirithromycin is a new macrolide with unusual pharmaco- 
kinetics characterized by a rapid and extensive distribution 
to the extravascular tissues and slow but constant elimina- 
tion from these tissues into the vascular spaces. It gives 
excellent evidence of the importance of the interrelation- 
ship between pharrnacokinetics and pharmacodynamics in 
determining dosage regimens for treating acute exacer- 
bations of chronic bronchitis. Pharmacokinetic data 
revealed that bronchial secretions contained a notable 
amount of antimicrobial activity (1.04 pug ml - i) 3 h after a 
single 500 mg dirithromycin dose; the prolonged half-life 
of the drug maintained significant concentrations of 
1.3 & 1.6 pug ml 12 h post-dose with a slow decrease, parallel 
to that in serum (Busch U. and Lechner U., abstract 
presented at the 28th ICAAC 1988). Most concentrations 
of dirithromycin in bronchial mucosa exceed 1 pug g- ’ 
4-24 h following a single 250 or 500 mg dose. After multiple 
doses at all sampling times (4, 12 and 24 h), concentrations 
were in the range 1.30-l .95 pg g - ‘. These results suggested 
the possibility of using once daily administration (41). In 
effect, several studies showed that dirithromycin 500 mg 
once daily for a minimum of 7 days and erythromycin 
1000 mg four times daily were comparable in the treatment 
of acute exacerbation of chronic bronchitis (42,43). Consid- 
ering the unusual pharmacokinetics of dirithromycin, we 
evaluated its pulmonary penetration in patients with acute 
exacerbation of chronic bronchitis after a 500 mg daily dose 
for 5 consecutive days treatment and observed that this 
macrolide was rapidly distributed into bronchial secretions 
and bronchial mucosa, where it persisted for up to 120 h 
following the last dose of drug (44). Mean concentrations 
were higher than MICs for many relevant respiratory 
micro-organisms and intracellular pathogens, but not for 
H. injuenzae. We obtained increased concentrations of the 
drug up to 72 h after the last dose with a fall in level after 
96 h. We speculated that this fall in levels might be 
explained by the fact that the inflammatory process 
decreased due to the antibacterial activity of dirithromycin. 
In fact, inflammation itself is likely to have a considerable 
effect on the ability of antibiotics to cross barriers (45). In 
view of this assumption, we also evaluated the clinical 
efficacy of a 5-day course of dirithromycin in patients 
suffering from acute exacerbation of severe COPD (46). The 
patients’ impressions of the daily course of the symptoms 
(dyspnea, cough and amount of sputum) were registered. A 
favourable symptomatic response to treatment (cure or 
improvement) was detected in 18 of 20 patients at post- 
therapy and, more importantly, our patients reported a 
clinical improvement for up to 72 h after the last dirithro- 
mycin dose. Moreover, notwithstanding its poor in vitro 
activity against H. injuenzae, dirithromycin was fairly 
effective against this micro-organism in viva. We assumed 
that these findings supported our hypothesis and the 
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possible existence of a relationship between pharmaco- 
kinetics and pharmacodynamics for this macrolide anti- 
biotic. Therefore, we suggested a shorter-term treatment 
than 7 days with dirithromycin for acute bacterial exacer- 
bations of chronic bronchitis (47) and a 5-day, once daily, 
dirithromycin regimen (500 mg day - ‘) has been proved to 
be as safe and as effective as a 7-day, four-times daily, 
erythromycin (1000 mg day ~ ‘) (Salisbury et al., abstract 
presented at the 33rd ICAAC, 1993, and Jones et cd., 
abstract presented at the 34th ICAAC, 1994). Later, we 
demonstrated that a different pulmonary pharmacokinetic 
behaviour might justify this shorter-term treatment with 
dirithromycin, help to explain the favourable responses 
observed in clinical studies and provide a rational basis for 
the treatment of exacerbated bronchitis (48). In fact a 
5-day, once daily, course of 500 mg dirithromycin induced 
higher concentrations and longer persistence in the various 
potential sites of pulmonary infection than a 7-day, 
every 6 h, course of 250 mg erythromycin and that a steady 
state of drug concentration was reached in lungs after five 
doses of dirithromycin, but not after 28 doses of erythro- 
mycin. It seems interesting to stress that the better activity 
of dirithromycin against H. influenzae could be due to the 
fact that the MICs of dirithromycin in the presence of 
serum in viva are five-fold lower than in vitro in artificial 
media (49) but also the persistence of antimicrobial activity 
in the tissues may be inhibitory for this pathogen (50). In 
fact, even if H. inyuenzae is not an obligate intracellular 
pathogen, it can reside at intracellular sites (51). 
Cefaclor is another proof of the role of the interrelation- 
ship between pharmacokinetics and pharmacodynamics in 
the antibiotic approach to exacerbations of chronic bron- 
chitis. This oral cephalosporin displays excellent activity 
against H. influenzae and M. catarrhalis, in addition to the 
bacterial pathogens typically susceptible to first-generation 
cephalosporins (52). It is rapidly absorbed when given by 
mouth, the mean peak plasma levels after a 500 mg dose 
being 779 mg l-- ’ at about 50 min (53). The plasma half-life 
is 0.5-I h. This pharmacokinetic profile allows a three- 
times daily dosage. A new extended release formulation 
(cefaclor MR) has been designed to have a slower rate of 
dissolution, which prolongs the absorption of the drug and 
decreases the maximum plasma concentration, but results 
in concentrations that persist for a longer period of time. 
Thus, a twice daily dosage is possible. When cefaclor MR 
and cefaclor are compared using a dose of 500 mg, the 
blood level curve with cefaclor MR is skewed to the right 
and the peak is lower than with cefaclor. However, with a 
dose of cefaclor MR of 750 mg twice daily, a different 
profile is seen. There is still a skew to the right but higher 
levels are achieved (54). The penetration into the sputum of 
500 mg cefaclor and 750 mg cefaclor MR after single and 
multiple administration has been studied in patients 
suffering from chronic bronchitis with hypersecretory 
disorder (55). The analysis of kinetic data showed that at 
2 h after the administration the sputum values of the 
cefaclor were higher (1.23 pug ml ~ ’ versus 0.37 pg m ~ ‘), 
but at 5 h the situation changed radically (0.46 pg ml ~ ’ 
versus 1.59pg ml ~ ‘). At 8 h measurable blood concen- 
trations were found only in the cefaclor MR group 
(0.20 pug ml - ‘). The peak sputum concentration was about 
15% of the serum concentration in cefaclor patients and 
about 17% in the cefaclor MR group. Given what is known 
of the pharmacodynamics of cephalosporins, it is reason- 
able to conclude that the optimum efficacy should be 
achieved when that cefaclor is administered every 6 h and 
cefaclor MR every 8 h. Nevertheless, it is reasonable 
to consider alternative dosage schedules that can be pre- 
dicted to achieve the required efficacy from our knowl- 
edge of interrelationship between pharmacokinetics and 
pharmacodynamics. If 5040% of the dosing interval 
should suffice for the treatment of acute exacerbations of 
chronic bronchitis, this finding applies to the concept of 
administering 8-h cefaclor and 12-h cefaclor MR. 
One interesting question is whether the failure of 
previous placebo-controlled studies to show benefit from 
treating acute exacerbations of chronic bronchitis with 
antibiotics should be explained by a lack of conformity to 
the strategies in pharmacokinetics and pharmacodynamics 
discussed above. We must highlight two very important 
points. First, bacteria have an in vivo comportment which 
can be different from that in vitro. For example, dirithro- 
mycin is more active in more natural conditions; in fact, its 
MICs against H. injluenzae are five-fold lower in the 
presence of serum (56) and, in any case, they are affected by 
assay conditions in vitro, such as composition, osmolarity 
and pH of the culture medium (57). It is very difficult to 
foresee what happens in the sites of infections. MICs 
probably change and these variations can definitely modify 
the interrelationship between pharmacodynamics and 
pharmacokinetics that is expected using the in vitro results. 
On the other hand, the patient population pharmaco- 
kinetics of an antibiotic that we usually use help to define 
the optimal population dosage regimen, but not necessarily 
that for an individual patient; the patient’s pharmaco- 
kinetics may differ from those of the population (58). 
Obviously, the optimal dosage regimen of an antibiotic 
would be more efficiently achieved if the individual’s dosage 
requirements could be calculated, prior to administering the 
drug, but this ideal cannot be totally met in practice. 
Conclusion 
Full knowledge of the interrelationships between pharma- 
codynamics and pharmacokinetics is important in choosing 
the appropriate antibiotic, determining its optimal dosing 
regimen and predicting which pharmacokinetic par- 
ameter(s) should best correlate with clinical efficacy. Based 
on the principles of pharmacodynamics as they relate to 
antimicrobials and by using the available microbiology and 
pharmacokinetic results, we are now able to formulate 
patient and pathogen-specific antibiotic dosing strategies 
that are adjusted to achieve therapeutic-significant cost 
savings without compromising therapeutic outcome. In this 
way, antibiotic therapy is also highly adaptable to patients 
suffering from acute exacerbations of chronic bronchitis. In 
any case, the major determinant for the application of any 
dosing regimen is its success in treating patients. 
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